Get the Stockscreener App
5.00
3.52%
0.17
After Hours:
5.00
Serina Therapeutics Inc stock is traded at $5.00, with a volume of 13,143.
It is up +3.52% in the last 24 hours and down -37.03% over the past month.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
See More
Previous Close:
$4.83
Open:
$4.84
24h Volume:
13,143
Relative Volume:
0.87
Market Cap:
$44.46M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-5.12%
1M Performance:
-37.03%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$4.84
$5.18
1-Week Range:
$4.557
$5.79
52-Week Range:
$3.81
$10.28
Serina Therapeutics Inc Stock (SER) Company Profile
Name
Serina Therapeutics Inc
Sector
Industry
Phone
(256) 327-9630
Address
601 GENOME WAY, HUNTSVILLE
Compare SER with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| SER | 5.00 | 44.46M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Serina Therapeutics Inc Stock (SER) Latest News
Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights - GlobeNewswire
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan - The Manila Times
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan - GlobeNewswire Inc.
TSX Composite Capped Index (TOOC) QuotePress Release - The Globe and Mail
AgeX Therapeutics stock hits 52-week low at $5.72 - Investing.com India
AgeX Therapeutics stock hits 52-week low at $5.72 By Investing.com - Investing.com Canada
Serina Therapeutics CDO Presents at Injectables Summit - TipRanks
Serina Therapeutics to Present at the 14th Annual Injectables Summit - GlobeNewswire
SLM initiated with a Buy at BofA - TipRanks
Serina Therapeutics director buys $6.9k in company stock By Investing.com - Investing.com Australia
Serina Therapeutics director buys $6.9k in company stock - Investing.com India
Biotech Soars On Material Transfer Agreement - Invezz
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Seelos Therapeutics Inc Inc. (SEEL) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Savaria (TSE:SIS) Trading Down 4.1% - MarketBeat
SThree Q3 net fees slip 8% amid challenging conditions - Staffing Industry Analysts
UK recruiter SThree falls on lower Q3 net fee - XM
SThree plc Navigates Market Headwinds in Q3 - TipRanks
Serabi Gold (LON:SRB) Reaches New 12-Month High at $91.97 - MarketBeat
Quarterly Metrics: Quick and Current Ratios for SELLAS Life Sciences Group Inc (SLS) - The Dwinnex
Ready to Jump After Recent Trade: SELLAS Life Sciences Group Inc (SLS) - SETE News
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval - Benzinga
Director Gregory Bailey Acquires 14,388 Shares of Serina Therapeutics Inc (SER) - Stockxpo
Serina Therapeutics director buys $88.2k in company stock By Investing.com - Investing.com South Africa
Serina Therapeutics director buys $88.2k in company stock - Investing.com
Sanofi (NASDAQ: SNY) Secures FDA Approval for Multiple Myeloma Drug in Newly Diagnosed Patients - ABBO News
Serina Therapeutics appoints new CEO with strategic goals By Investing.com - Investing.com Australia
Serina Therapeutics appoints new CEO with strategic goals - Investing.com
Serina Therapeutics Names Steven Ledger as Permanent CEO - TipRanks
Serina Therapeutics Interim CEO Attends Global Investment Conference - TipRanks
Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Serina Therapeutics director buys $14.7k in company stock - Investing.com
Serina Therapeutics director buys $140k in company stock - Investing.com India
Director Gregory Bailey Acquires 19,200 Shares of Serina Therapeutics Inc (SER) - Yahoo Finance
Serina Therapeutics director buys $45k in company stock - Investing.com
Serina Therapeutics Welcomes Gregory Curhan as New CFO - TipRanks
Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights - GlobeNewswire
Nima Farzan named CEO of Latigo - BioCentury
Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation - GlobeNewswire
Injectable Drug Delivery Market Size to Hit USD 1,630.73 Bn by 2033 - BioSpace
Enable Injections makes C-suite move following slew of new partnershipsCincinnati Business Courier - Cincinnati Business Courier
Enable Injections & Serina Partner to Develop Novel Parkinson’s Treatment - HIT Consultant
Enable Injections and Serina Therapeutics Announce - GlobeNewswire
Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights - Yahoo Finance
Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman - GlobeNewswire
Why VirTra Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving PremarketVirTra (NASDAQ:VTSI) - Benzinga
Serina completes AgeX merger, targets neurological diseases and pain - Longevity.Technology
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics - GlobeNewswire
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results - Yahoo Finance
AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc.AGE - Business Wire
AgeX Therapeutics Postpones Merger Completion with Serina - TipRanks
Serina Therapeutics Inc Stock (SER) Financials Data
There is no financial data for Serina Therapeutics Inc (SER). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Cap:
|
Volume (24h):